57 completed, 14 recruiting, 10 unknown, 6 terminated. 102 Phase 3, 14 Phase 2.
Follow Solutions: new trials by email Literature Review of Solutions trials Research Report on Solutions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stratification and Treatment in Early Psychosis Study -ASSIST CBD 100 mg/mL Oral Solution, Placeb - Treatment Resistant Psychosis, Psychosis | Phase 3 | Not yet recruiting | University of Oxford | 250 | 2027-01-01 | 2026-10-08 |
| A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immune globulin (human) 10% solution for intravenous administration - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Kedrion S.p.A. | 161 | 2026-11-01 | 2026-11-05 |
| Stratification and Treatment in Early Psychosis Study - ENHANCE CBD 100 mg/mL Oral Solution, Placebo - Psychosis, First Episode Psychosis | Phase 3 | Recruiting | University of Oxford | 250 | 2026-10-05 | 2026-10-08 |
| Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol - Opioid Use Disorder | Phase 3 | Not yet recruiting | Montefiore Medical Center | 40 | 2026-10-01 | 2026-06-09 |
| A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion) - Acute Pain | Phase 3 | Recruiting | AFT Pharmaceuticals, Ltd. | 60 | 2026-09-14 | 2026-09-16 |
| Androgenic Alopecia TH07 Clinical Trial TH07, Minoxidil 5% Topical Solution, Placebo - Androgenic Alopecia | Phase 3 | Recruiting | Triple Hair Inc | 420 | 2026-04-01 | 2026-03-16 |
| Comparative Efficacy Of 4 mg VS. 8 mg Submucosal Dexamethasone In Postoperative Pain Management After Dental Implant Surgery: A Randomized Double-Blind Controlled Clinical Trial Dexamethasone 4 Mg/mL Injectable Solution, Dexamethasone 8Mg Solution for Injection, Saline (NaCl 0,9 %) (placebo) - Postoperative Pain | Phase 3 | Recruiting | Oman Ministry of Health | 138 | 2026-03-25 | 2026-03-30 |
| Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II. Arnica Tincture, Meglumine antimoniate. - Leishmaniasis, Cutaneous | Phase 3 | Recruiting | Universidad de Antioquia | 96 | 2026-03-11 | 2026-04-02 |
| Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study) Human Albumin 20% Solution, Standard Care (in control arm) - Critical Illness, Septic Shock | Phase 3 | Not yet recruiting | Mahidol University | 304 | 2025-12-01 | 2025-11-19 |
| Efficacy and Safety of Sodium Hyaluronate Gel Combined With Sodium Bicarbonate Versus Sodium Bicarbonate Alone in Prevention of Failed Back Surgery Syndrome Sodium hyaluronate jell, Sodium Bicarbonate, Saline - Postdiscectomy Epidural Fibrosis, Pain | Phase 2 / Phase 3 | Active not recruiting | Misr University for Science and Technology | 60 | 2025-06-20 | 2025-07-29 |
| A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) TAK-881, HYQVIA, SC Investigational Needle Sets - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 3 | Recruiting | Takeda | 59 | 2025-05-06 | 2026-01-20 |
| Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID) Crofelemer Powder for Oral Solution, Placebo Powder for Oral Solution - Microvillus Inclusion Disease, Congenital Disorders | Phase 2 / Phase 3 | Active not recruiting | Napo Pharmaceuticals, Inc. | 6 | 2025-05-01 | 2026-06-09 |
| 5-Aminolevulinic Acid for Photodynamic Diagnosis of Malignant Glioma 5-Aminolevulinic Acid Hydrochloride Powder for Oral Solution - 5-aminolevulinic Acid, Fluorescence-guided Resection | Phase 3 | Recruiting | Lee's Pharmaceutical Limited | 79 | 2025-04-14 | 2026-10-27 |
| Comparing Prophylactic Intravenous Pethidine and Intrathecal Pethidine in Preventing Post Spinal Shivering in Caesarean Section Pethidine Hydrochloride 50 Mg/mL Solution for Injection, Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally - Pregnant Women | Phase 3 | Recruiting | Alexandria University | 86 | 2024-12-10 | 2025-01-15 |
| A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases TAK-881, Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US) - Primary Immunodeficiency Diseases (PID) | Phase 3 | Active not recruiting | Takeda | 53 | 2024-11-04 | 2026-04-08 |
| Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia. TAD® 600 mg/4 mL powder and solvent for solution for injection, Saline solution 0.9% of sodium chloride - Pneumonia, Myocardial Injury | Phase 3 | Unknown | Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica | 178 | 2024-06-25 | 2024-11-27 |
| Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction Belatacept 250 Milligram Intravenous Powder for Solution - Chronic Kidney Failure | Phase 3 | Recruiting | Nantes University Hospital | 30 | 2024-05-03 | 2026-11-13 |
| The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION, Placebo - Brain Tumor, Bleeding | Phase 3 | Recruiting | Stephen Lownie | 102 | 2024-04-03 | 2026-03-19 |
| Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection - Progressive Multifocal Leukoencephalopathy | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 33 | 2024-04-01 | 2024-02-26 |
| Certolizumab in Recurrent Implantation Failure (RIF) Certolizumab (CIMZIA® ; TNF-α antagonist), Placebo (NaCl 0.9 % solution) - Recurrent Unexplained Implantation Failure | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 161 | 2023-11-30 | 2023-12-11 |
Showing 20 of 102. Sign in to see all of them.
Alopecia (5) · Ocular Hypertension (5) · Pain, Postoperative (5) · Glaucoma, Open-Angle (4) · Primary Immunodeficiency Diseases (4) · Pain (3) · Anemia (2) · Arthritis (2) · COVID-19 (2) · Critical Illness (2) · Foot Dermatoses (2) · Hemorrhage (2) · Keratoderma, Palmoplantar, Epidermolytic (2) · Keratosis, Actinic (2) · Kidney Failure, Chronic (2)
Alcon Research (6) · Baxalta now part of Shire (4) · Merck Sharp & Dohme LLC (3) · Pfizer (3) · Takeda (3) · Assistance Publique - Hôpitaux de Paris (2) · Baxter Healthcare Corporation (2) · Cassiopea SpA (2) · DUSA Pharmaceuticals, Inc. (2) · GlaxoSmithKline (2) · Lannett Company, Inc. (2) · Lee's Pharmaceutical Limited (2) · Montefiore Medical Center (2) · Nantes University Hospital (2) · Sandoz (2)
United States (35) · Canada (11) · Germany (11) · Spain (10) · France (9) · Poland (8) · Italy (7) · Denmark (6) · United Kingdom (6) · Belgium (5) · Greece (5) · Switzerland (5) · Brazil (4) · Czechia (4) · Egypt (4)
Alessandro Mazzetti, M.D. (2) · Stuart Marcus, MD, PhD (2) · Amani Khairy, Professor (1) · Andrea Vetter, Dr. (1) · Anuj Bhatia, MD FRCPC (1) · Arnaud Garnier, MD (1) · Ashkan Mortezavi, MD, PhD (1) · Belaid BB Bouhemad, PU-PH (1) · Benjamin BC Chousterman, PH (1)
PMID 26718625, PMID 18538406, PMID 18687132, PMID 19194156, PMID 19365194, PMID 19668532, PMID 20554319, PMID 21656179, PMID 23960389, PMID 24266542, PMID 24643895, PMID 24672709, PMID 25365753, PMID 25534062, PMID 25558198, PMID 26060513, PMID 26214039, PMID 27007959, PMID 27355541, PMID 27418050, PMID 27459266, PMID 27582171, PMID 2788589, PMID 28283245, PMID 28871961, PMID 29300876, PMID 29408333, PMID 29897841, PMID 30016540, PMID 30626238, PMID 30886475, PMID 31136331, PMID 31228628, PMID 31268374, PMID 31831982, PMID 32040014, PMID 32335895, PMID 32586393, PMID 33212068, PMID 33693990, PMID 33774745, PMID 33781988, PMID 33822015, PMID 33879722, PMID 34003796, PMID 34036490, PMID 34190962, PMID 34219224, PMID 34219653, PMID 34305948
2019 (2), 2023 (2), 2025 (2), 2004 (1), 2005 (1), 2008 (1), 2009 (1), 2014 (1), 2015 (1), 2016 (1), R34DA063987 (1)